Strabismus in retinoblastoma survivors with long-term follow-up

被引:5
作者
Fabian, Ido D.
Stacey, Andrew W.
Naeem, Zishan
Onadim, Zerrin
Chowdhury, Tanzina
Duncan, Catriona
Sagoo, Mandeep S.
Reddy, M. Ashwin
机构
[1] Retinoblastoma Service, Royal London Hospital, London
[2] Ocular Oncology Service, Goldschleger Eye Institute, Sheba Medical Center, Tel-Aviv University, Tel Aviv
[3] Department of Ophthalmology, University of Washington, Seattle, Washington
[4] Paediatric Oncology Department, Great Ormond Street Hospital, London
[5] National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London
来源
JOURNAL OF AAPOS | 2018年 / 22卷 / 04期
关键词
D O I
10.1016/j.jaapos.2018.03.007
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To report the long-term strabismus rate in salvaged retinoblastoma (Rb) patients and investigate possible risk factors leading to strabismus. Methods: The medical records of patients with Rb presenting at a single institution over a 9-year period were reviewed retrospectively with regard to ocular alignment outcomes after long-term follow-up. Results: A total of 64 eyes of 42 patients (22 bilateral cases [52%]) were included, presenting with International Intraocular Retinoblastoma Classification (IIRC) in the worse eye as follows: group A (n = 1), B (n = 16), C (n = 12), D (n = 11), no Rb (n = 2). Fifteen patients (36%) were initially referred because of family history of Rb. Mean age at presentation was 8.2 months (range, 0.3-58.3 months). Overall treatments included intravenous chemotherapy (62 eyes), intraophthalmic artery chemotherapy (10 eyes), brachytherapy (11 eyes), transpupillary thermotherapy (22 eyes), cryotherapy (47 eyes), and external beam radiotherapy (4 eyes). At final follow-up (mean, 93.7 months), 69% of patients had strabismus, with exotropia being the most common type (n = 18), followed by esotropia (n = 8), and alternate exotropia/esotropia (n = 3). On univariate analysis, the worse eye group IIRC and cTNMH, sporadic cases, strabismus, and foveal tumor at presentation were found to be significantly associated with strabismus at final follow-up (P ≤ 0.043). On multivariate analysis, only foveal involvement was found to be significant (P < 0.001). Conclusions: Strabismus, exotropia in particular, is a common adverse sequela following successful conservative treatment for Rb, with 69% of the present cohort having some type of deviation after long-term follow-up, for which foveal tumor at presentation was found to be a significant risk factor. © 2018 American Association for Pediatric Ophthalmology and Strabismus
引用
收藏
页码:276 / 276
页数:1
相关论文
共 15 条
[1]  
Kivela T., The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death, Br J Ophthalmol, 93, pp. 1129-1131, (2009)
[2]  
Shields C.L., Meadows A.T., Leahey A.M., Shields J.A., Continuing challenges in the management of retinoblastoma with chemotherapy, Retina, 24, pp. 849-862, (2004)
[3]  
Shields C.L., Douglass A.M., Beggache M., Say E.A., Shields J.A., Intravitreous chemotherapy for active vitreous seeding from retinoblastoma: outcomes after 192 consecutive injections. The 2015 Howard Naquin Lecture, Retina, 36, pp. 1184-1190, (2016)
[4]  
Abramson D.H., Daniels A.B., Marr B.P., Et al., Intra-arterial chemotherapy (ophthalmic artery chemosurgery) for group D retinoblastoma, PLoS One, 11, (2016)
[5]  
Fabian I.D., Naeem Z., Stacey A.W., Et al., Long-term visual acuity, strabismus, and nystagmus outcomes following multimodality treatment in group D retinoblastoma eyes, Am J Ophthalmol, 179, pp. 137-144, (2017)
[6]  
Linn Murphree A., Intraocular retinoblastoma: the case for a new group classification, Ophthalmol Clin North Am, 18, pp. 41-53, (2005)
[7]  
Mallipatna A.C., Gallie B.L., Chevez-Barrios P., Et al., Retinoblastoma, AJCC Cancer Staging Manual, pp. 819-831, (2017)
[8]  
Muen W.J., Kingston J.E., Robertson F., Brew S., Sagoo M.S., Reddy M.A., Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma, Ophthalmology, 119, pp. 611-616, (2012)
[9]  
The ischemic optic neuropathy decompression trial (IONDT): design and methods, Control Clin Trials, 19, pp. 276-296, (1998)
[10]  
Watts P., Westall C., Colpa L., Et al., Visual results in children treated for macular retinoblastoma, Eye (Lond), 16, pp. 75-80, (2002)